The safety of indacaterol for the treatment of COPD

References

• GOLD. 2017. Global Strategy for the Diagnosis, Management and Prevention of COPD. [cited 2018 Feb 10]. Available from: http://goldcopd.org/download/326/
   Google Scholar
• Meng YY, Leung KM, Berkbigler D, et al. Compliance with US asthma management guidelines and specialty care: a regional variation or national concern? J Eval Clin Pract. 1999;5:213–221.
   PubMed Web of Science ®Google Scholar
• Battram C, Charlton SJ, Cuenoud B, et al. In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther. 2006;317:762–770.
   PubMed Web of Science ®Google Scholar
• Scola AM, Loxham M, Charlton SJ, et al. The long-acting β-adrenoceptor agonist, indacaterol, inhibits IgE-dependent responses of human lung mast cells. Br J Pharmacol. 2009;158:267–276.
   PubMed Web of Science ®Google Scholar
• Hosoe M, Woessner R, Matsushima S, et al. Efficacy, safety and pharmacokinetics of indacaterol in Caucasian and Japanese patients with chronic obstructive pulmonary disease: a comparison of data from two randomized, placebo-controlled studies. Clin Drug Investig. 2011;31:247–255.
   PubMed Web of Science ®Google Scholar
• Jiang J, Li L, Hequn B, et al. Single- and multiple-dose pharmacokinetics of inhaled indacaterol in healthy Chinese volunteers. Eur J Drug Metab Pharmacokinet. 2015;40:203–208.
   PubMed Web of Science ®Google Scholar
• Rennard S, Bantje T, Centanni S, et al. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med. 2008;102:1033–1044.
   PubMed Web of Science ®Google Scholar
• Yum HK, Kim HR, Chang Y, et al. Safety and effectiveness of indacaterol in chronic obstructive pulmonary disease patients in South Korea. Tuberc Respir Dis (Seoul). 2017;80:52–59.
   PubMed Web of Science ®Google Scholar
• Kagan M, Dain J, Peng L, et al. Metabolism and pharmacokinetics of indacaterol in humans. Drug Metab Dispos. 2012;40:1712–1722.
   PubMed Web of Science ®Google Scholar
• Sturton RG, Trifilieff A, Nicholson AG, et al. Pharmacological characterization of indacaterol, a novel once daily inhaled 2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices. J Pharmacol Exp Ther. 2008;324:270–275.
   PubMed Web of Science ®Google Scholar
• Naline E, Trifilieff A, Fairhurst RA, et al. Effect of indacaterol, a novel long-acting b 2 -agonist, on isolated human bronchi. Eur Respir J. 2007;29:575–581.
   PubMed Web of Science ®Google Scholar
• Donohue JF. Minimal clinically important differences in COPD lung function. COPD. 2005;2:111–124.
   PubMedGoogle Scholar
• Cazzola M, Macnee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008;31:416–469.
   PubMed Web of Science ®Google Scholar
• Renard D, Looby M, Kramer B, et al. Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches. Respir Res. 2011;12:54.
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Pocock SJ, Magnussen H, et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulm Pharmacol Ther. 2010;23:165–171.
   PubMed Web of Science ®Google Scholar
• Cope S, Zhang J, Williams J, et al. Efficacy of once-daily indacaterol 75μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysis. BMC Pulm Med. 2012;12:29.
   PubMed Web of Science ®Google Scholar
• Donohue JF, Fogarty C, Lötvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010;182:155–162.
   PubMed Web of Science ®Google Scholar
• Feldman G, Siler T, Prasad N, et al. Efficacy and safety of indacaterol 150μg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med. 2010;10:11.
   PubMed Web of Science ®Google Scholar
• Dahl R, Chung KF, Buhl R, et al. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010;65:473–479.
   PubMed Web of Science ®Google Scholar
• Kerwin EM, Gotfried MH, Lawrence D, et al. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged 40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies. Clin Ther. 2011;33:1974–1984.
   PubMed Web of Science ®Google Scholar
• Donohue J, Singh D, Kornmann O, et al. Safety of indacaterol in the treatment of patients with COPD. Int J Chron Obstruct Pulmon Dis. 2011;6:477–492.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Segreti A, Stirpe E, et al. Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol. Respir Med. 2013;107:107–111.
   PubMed Web of Science ®Google Scholar
• Beeh KM, Derom E, Kanniess F, et al. Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma. Eur Respir J. 2007;29:871–878.
   PubMed Web of Science ®Google Scholar
• Pearlman DS, Greos L, LaForce C, et al. Bronchodilator efficacy of indacaterol, a novel once-daily beta2-agonist, in patients with persistent asthma. Ann Allergy Asthma Immunol. 2008;101:90–95.
   PubMed Web of Science ®Google Scholar
• Sugihara N, Kanada S, Haida M, et al. 24-h bronchodilator efficacy of single doses of indacaterol in Japanese patients with asthma: a comparison with placebo and salmeterol. Respir Med. 2010;104:1629–1637.
   PubMed Web of Science ®Google Scholar
• Vaidya SS, Khindri S, Calder N, et al. Pharmacokinetics of indacaterol and mometasone furoate delivered alone or in a free or fixed dose combination in healthy subjects. Pulm Pharmacol Ther. 2016;37:30–36.
   PubMed Web of Science ®Google Scholar
• Assessment report for Onbrez Breezhaler. European Medicines Agency Evaluation of Medicines for Human Use. 2009. [cited 2018 Feb 10]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001114/WC500053735.pdf
   Google Scholar
• Summary review of regulatory action. FDA/Center for Drug Evaluation and Research. 2011. [cited 2018 Feb 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383orig1s000sumr.pdf
   Google Scholar
• Chowdhury BA, Dal Pan G. The FDA and safe use of long-acting beta-Agonists in the treatment of asthma. N Engl J Med. 2010;362:1169–1171.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Reddel HK, van Zyl-Smit RN, et al. The asthma-COPD overlap syndrome: towards a revised taxonomy of chronic airways diseases? Lancet Respir Med. 2015;3:719–728.
   PubMed Web of Science ®Google Scholar
• FDA review finds no significant increase in risk of serious asthma outcomes with long-acting beta agonists (LABAs) used in combination with inhaled corticosteroids (ICS): FDA/Center for Drug Evaluation and Research. 2017. [cited 2018 Feb 10]. Available from: https://www.fda.gov/downloads/Drugs/DrugSafety/UCM589997.pdf.
   Google Scholar
• Newnham DM, McDevitt DG, Lipworth BJ, et al. Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthma. Am J Med. 1994;97:29–37.
   PubMed Web of Science ®Google Scholar
• Grove A, Lipworth BJ. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet (London, England). 1995;346:201–206.
   PubMed Web of Science ®Google Scholar
• Cheung D, Timmers MC, Zwinderman AH, et al. Long-term effects of a long-acting b2 -adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med. 1992;327:1198–1203.
   PubMed Web of Science ®Google Scholar
• Insulander P, Juhlin-Dannfelta A, Freyschuss U, et al. Electrophysiologic effects of salbutamol, a β2-selective agonist. J Cardiovasc Electrophysiol. 2004;15:316–322.
   PubMed Web of Science ®Google Scholar
• Chapman KR, Rennard SI, Dogra A, et al. Long-term safety and efficacy of indacaterol, a long-acting β-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest. 2011;140:68–75.
   PubMed Web of Science ®Google Scholar
• Worth H, Chung KF, Felser JM, et al. Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med. 2011;105:571–579.
   PubMed Web of Science ®Google Scholar
• Gershon A, Croxford R, Calzavara A, et al. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med. 2013;173:1175.
   PubMed Web of Science ®Google Scholar
• Xia N, Wang H, Nie X. Inhaled long-acting β2-agonists do not increase fatal cardiovascular adverse events in COPD: a meta-analysis. PLoS One. 2015;10:e0137904.
   PubMed Web of Science ®Google Scholar
• Wang MT, Liou JT, Lin CW, et al. Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease. JAMA Intern Med. 2018;178:229-238.
   Web of Science ®Google Scholar
• Matsushima S, Matthews I, Woessner R, et al. Systemic pharmacokinetics of indacaterol, an inhaled once-daily long-acting b2-agonist, in different ethnic populations. Int J Clin Pharmacol Ther. 2012;50:545–556.
   PubMed Web of Science ®Google Scholar
• Girodet P, Jasnot J, Gros VL, et al. Efficacy and safety of indacaterol in patients with chronic obstructive pulmonary disease aged over 65 years: a pooled analysis. Respir Med. 2017;128:1–10.
   PubMed Web of Science ®Google Scholar
• Juvelekian G, El-Sorougi W, Pothirat C, et al. A real-world evaluation of indacaterol and other bronchodilators in COPD: the INFLOW study. Int J Chron Obstruct Pulmon Dis. 2015;10:2109–2120.
   PubMed Web of Science ®Google Scholar
• Park J, Lee JS, Rhee C, et al. Effect of indacaterol on cough and phlegm in chronic obstructive pulmonary disease patients: a meta-analysis of five randomized controlled trials. J Korean Med Sci. 2015;30:1453–1458.
   PubMed Web of Science ®Google Scholar
• Ohno T, Wada S, Hanada S, et al. Efficacy of indacaterol on quality of life and pulmonary function in patients with COPD and inhaler device preferences. Int J Chron Obstruct Pulmon Dis. 2014;9:107–114.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42:1484–1494.
   PubMed Web of Science ®Google Scholar
• Vincken W, Aumann J, Chen H, et al. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study. Int J Chron Obstruct Pulmon Dis. 2014;9:215–228.
   PubMed Web of Science ®Google Scholar
• Prakash A, Babu KS, Morjaria JB. Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:111–123.
   PubMed Web of Science ®Google Scholar
• Mahler DA, Kerwin E, Ayers T, et al. FLIGHT1 and FLIGHT2: efficacy and safety of QVA149 (Indacaterol/Glycopyrrolate) versus its monocomponents and placebo in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192:1068–1079.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Page C. Long-acting bronchodilators in COPD: where are we now and where are we going? Breathe. 2014;10:110–120.
   Google Scholar
• Montes de Oca M, López Varela MV, Acuña A, et al. ALAT-2014 chronic obstructive pulmonary disease (COPD) clinical practice guidelines: questions and answers. Arch Bronconeumol. 2015;51:403–416.
   PubMed Web of Science ®Google Scholar
• Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155:179–191.
   PubMed Web of Science ®Google Scholar
• Jiangna H, Dai L, Nanshan Z. Indacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized placebo-controlled trials. BMC Pulm Med. 2013;13:26.
   PubMed Web of Science ®Google Scholar
• Geake JB, Dabscheck EJ, Wood-Baker R, et al. Indacaterol, a once-daily beta2-agonist, versus twice-daily beta2-agonists or placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015;10:1.
   Google Scholar
• Kim JS, Park J, Lim SY, et al. Comparison of clinical efficacy and safety between indacaterol and tiotropium in COPD:meta-analysis of randomized controlled trials. Plos One. 2015;10:e0119948.
   PubMed Web of Science ®Google Scholar
• Price D, Gray A, Gale R, et al. Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD. Respir Med. 2011;105:1635–1647.
   PubMed Web of Science ®Google Scholar
• Price D, Asukai Y, Ananthapavan J, et al. A UK-based cost-utility analysis of indacaterol, a once-daily maintenance bronchodilator for patients with COPD, using real world evidence on resource use. Appl Health Econ Health Policy. 2013;11:259–274.
   PubMedGoogle Scholar
• Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;9:2222–2234.
   Google Scholar